Skip to main content

Table 2 Outcomes of singleton pregnancies with LPV/r exposure (n=4762)

From: Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

Total live births, n (%) 4556 (95.7)
ᅟConception on LPV/r, n 863
ᅟInitiation of LPV/r, n 3693
Mode of delivery, n (%) n=4541
ᅟVaginal delivery 1664 (36.6)
ᅟElective caesarean delivery 1776 (39.1)
ᅟEmergency caesarean delivery 1101 (24.3)
Gestational age n=4556
ᅟMedian (IQR), wk 38 (38–39)
ᅟ<32 wk, n (%) 112 (2.5)
ᅟ32–36 wk, n (%) 473 (10.4)
ᅟ≥37 wk, n (%) 3971 (87.2)
Birth weight n=4395
ᅟMedian (IQR), g 3030 (2710–3360)
ᅟ<1500 g, n (%) 101 (2.3)
ᅟ1500–2499 g, n (%) 545 (12.4)
ᅟ≥2500 g, n (%) 3749 (85.3)
Infant mortality, n 24
ᅟRate by gestational age
ᅟᅟ<32 wk, n/N, per 1000 infants (95 % CI) 14/112, 125.0 per 1000 infants (62.8–187.2)
ᅟᅟ32–36 wk, n/N, per 1000 infants (95 % CI) 4/473, 8.5 per 1000 infants (0.2–16.7)
ᅟᅟTerm, n/N, per 1000 infants (95 % CI) 6/3971, 1.5 per 1000 infants (0.3–2.7)
Stillbirth, n (%) 44 (0.9)
ᅟConception on LPV/r, n/N (%) 7/952 (0.7)
ᅟInitiation of LPV/r, n/N (%) 37/3810 (1.0)
ᅟRate by gestational age
ᅟᅟ<32 wk, n/N, per 1000 infants (95 % CI) 23/135, 170.4 per 1000 infants (106.1–234.6)
ᅟᅟ32–36 wk, n/N, per 1000 infants (95 % CI) 8/481, 16.6 per 1000 infants (5.2–28.1)
ᅟᅟTerm, n/N, per 1000 infants (95 % CI) 13/3984, 3.3 per 1000 infants (1.5–5.0)
Miscarriage or termination,a n (%) 120 (2.5)
ᅟConception on LPV/r, n/N (%) 76/952 (8.0)
ᅟInitiation of LPV/r, n/N (%) 44/3810 (1.2)
Left United Kingdom/Ireland before delivery, n (%) 42 (0.9)
  1. Abbreviations: LPV/r lopinavir/ritonavir, IQR interquartile range
  2. aBased on data reported from antenatal care providers